'
대장암 환자의 옥살리플라틴(oxaliplatin) 유도 말초신경병증에 대한 약물유전학적 접근: 체계적 문헌고찰' 의 주제별 논문영향력
| 주제 |
|
|
|---|---|---|
| 동일주제 총논문수 | 논문피인용 총횟수 | 주제별 논문영향력의 평균 |
| 2,361 | 0 |
0.0% |
주제별 논문영향력
' 대장암 환자의 옥살리플라틴(oxaliplatin) 유도 말초신경병증에 대한 약물유전학적 접근: 체계적 문헌고찰' 의 참고문헌
-
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter studyArgyriou AA [2013]
-
Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinomaLai JI [2009]
-
Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN)Argyriou A [2015]
-
Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseasesChaudhary R [2015]
-
Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathwayGamelin L [2007]
-
Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patientsKumamoto K [2013]
-
Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicityBasso M [2011]
-
Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patientsWon HH [2012]
-
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysisHong J [2011]
-
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapyRuzzo A [2007]
-
Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: A GEMCAD group studyCustodio A [2014]
-
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741McLeod HL [2010]
-
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapyPare L [2008]
-
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05Boige V [2010]
-
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancerLee KH [2013]
-
Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and preventionGrisold W [2012]
-
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysisZarate R [2010]
-
NCCN task force report: Management of neuropathy in cancerStubblefield MD [2009]
-
Management of side effects in the personalized medicine era: Chemotherapy-induced peripheral neuropathyAlberti P [2014]
-
Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathyArgyriou AA [2009]
-
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)Kanai M [2016]
-
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced nonsmall cell lung cancerChang MH [2009]
-
Integrin beta-3 L33P: A new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?Antonacopoulou AG [2010]
-
Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinomaChen YC [2010]
-
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancerArgyriou AA [2007]
-
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapyLecomte T [2006]
-
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathySereno M [2017]
-
Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancerOguri T [2013]
-
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysisTerrazzino S [2015]
-
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitorsCalvo E [2006]
-
Differential toxicity biomarkers for irinotecan-and oxaliplatin-containing chemotherapy in colorectal cancerCortejoso L [2013]
-
Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment toolTofthagen CS [2011]
-
Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel testsDi Francia R [2013]
-
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomicsCavaletti G [2011]
-
Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literatureArgyriou A [2014]
-
Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genesInada M [2010]
-
Associations between glutathione S-transferase Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathyKanai M [2010]
-
Associations between UGT1A1* 6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patientsHan FF [2014]
-
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trialBraun MS [2009]
-
Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancerStoehlmacher J [2002]
-
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomasTaron M [2005]
-
A review on oxaliplatin-induced peripheral nerve damageArgyriou AA [2008]
-
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimenCecchin E [2013]